S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
7 Stocks That Will Drive the Weight Loss Drugs Market
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
7 Stocks That Will Drive the Weight Loss Drugs Market
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
7 Stocks That Will Drive the Weight Loss Drugs Market
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
7 Stocks That Will Drive the Weight Loss Drugs Market
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
NASDAQ:ANNX

Annexon (ANNX) Stock Price, News & Analysis

$7.17
-0.64 (-8.19%)
(As of 03/28/2024 ET)
Today's Range
$7.03
$8.26
50-Day Range
$4.03
$7.81
52-Week Range
$1.57
$8.40
Volume
4.06 million shs
Average Volume
1.52 million shs
Market Capitalization
$381.73 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$14.14

Annexon MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
97.3% Upside
$14.14 Price Target
Short Interest
Healthy
4.68% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.41mentions of Annexon in the last 14 days
Based on 23 Articles This Week
Insider Trading
Selling Shares
$49,514 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($1.65) to ($1.53) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.54 out of 5 stars

Medical Sector

314th out of 938 stocks

Pharmaceutical Preparations Industry

142nd out of 432 stocks

ANNX stock logo

About Annexon Stock (NASDAQ:ANNX)

Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune, neurodegenerative, and ophthalmic disorders. The company's C1q is an initiating molecule of the classical complement pathway that targets distinct disease processes, such as antibody-mediated autoimmune disease and complement-mediated neurodegeneration. Its product candidates include ANX005, a monoclonal antibody, which is in Phase II/III clinical trials to treat patients with guillain- barré syndrome; Phase II trial in patients with warm autoimmune hemolytic anemia; and Phase II clinical trial for Huntington's disease and amyotrophic lateral sclerosis. The company is also developing ANX009 that is in Phase Ib trial in patients with lupus nephritis; and ANX007, which is in Phase II clinical trials to treat patients with geographic atrophy. In addition, it develops ANX105, an investigational monoclonal antibody targeting neurodegenerative indications; and ANX1502, an investigational oral small molecule for the treatment of certain autoimmune indications. The company was incorporated in 2011 and is headquartered in Brisbane, California.

ANNX Stock Price History

ANNX Stock News Headlines

Central Banks Preparing for US Dollar Collapse?
China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.
Annexon (NASDAQ:ANNX) Receives Buy Rating from HC Wainwright
Central Banks Preparing for US Dollar Collapse?
China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.
Annexon Biosciences (ANNX) Receives a Buy from TD Cowen
ANNX Jul 2024 7.500 put
ANNX Apr 2024 2.500 call
ANNX Apr 2024 7.500 put
HRTX, LUNA and ARQ among mid-day movers
ANNX Mar 2024 10.000 put
JP Morgan Upgrades Annexon (ANNX)
Annexon Stock (NASDAQ:ANNX), Short Interest Report
ANNX Mar 2024 5.000 call
See More Headlines
Receive ANNX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Annexon and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/13/2023
Today
3/28/2024
Next Earnings (Estimated)
5/13/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:ANNX
Employees
76
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$14.14
High Stock Price Target
$30.00
Low Stock Price Target
$7.00
Potential Upside/Downside
+89.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
6 Analysts

Profitability

Net Income
$-141,950,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$4.85 per share

Miscellaneous

Free Float
43,065,000
Market Cap
$381.73 million
Optionable
Optionable
Beta
1.10
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Key Executives


ANNX Stock Analysis - Frequently Asked Questions

Should I buy or sell Annexon stock right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Annexon in the last twelve months. There are currently 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ANNX shares.
View ANNX analyst ratings
or view top-rated stocks.

What is Annexon's stock price target for 2024?

6 equities research analysts have issued 12 month price targets for Annexon's shares. Their ANNX share price targets range from $7.00 to $30.00. On average, they expect the company's stock price to reach $14.14 in the next year. This suggests a possible upside of 97.3% from the stock's current price.
View analysts price targets for ANNX
or view top-rated stocks among Wall Street analysts.

How have ANNX shares performed in 2024?

Annexon's stock was trading at $4.54 at the beginning of the year. Since then, ANNX stock has increased by 57.9% and is now trading at $7.17.
View the best growth stocks for 2024 here
.

Are investors shorting Annexon?

Annexon saw a increase in short interest during the month of March. As of March 15th, there was short interest totaling 2,490,000 shares, an increase of 27.7% from the February 29th total of 1,950,000 shares. Based on an average daily trading volume, of 1,630,000 shares, the short-interest ratio is currently 1.5 days.
View Annexon's Short Interest
.

When is Annexon's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 13th 2024.
View our ANNX earnings forecast
.

How were Annexon's earnings last quarter?

Annexon, Inc. (NASDAQ:ANNX) announced its quarterly earnings data on Monday, November, 13th. The company reported ($0.43) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.50) by $0.07.

What ETFs hold Annexon's stock?

ETFs with the largest weight of Annexon (NASDAQ:ANNX) stock in their portfolio include Simplify Propel Opportunities ETF (SURI).iShares Neuroscience and Healthcare ETF (IBRN).

What other stocks do shareholders of Annexon own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Annexon investors own include Alibaba Group (BABA), CVS Health (CVS), Home Depot (HD), Procter & Gamble (PG), Johnson & Johnson (JNJ), RTX (RTX), Thermo Fisher Scientific (TMO), Cisco Systems (CSCO) and Pfizer (PFE).

When did Annexon IPO?

Annexon (ANNX) raised $150 million in an initial public offering on Friday, July 24th 2020. The company issued 10,000,000 shares at $14.00-$16.00 per share. J.P. Morgan, BofA Securities and Cowen served as the underwriters for the IPO.

Who are Annexon's major shareholders?

Annexon's stock is owned by a number of institutional and retail investors. Top institutional investors include Bain Capital Life Sciences Investors LLC (15.14%), BVF Inc. IL (13.15%), Vanguard Group Inc. (3.58%), Vanguard Group Inc. (3.58%), Vontobel Holding Ltd. (1.22%) and Sectoral Asset Management Inc. (1.22%). Insiders that own company stock include Bain Capital Life Sciences Inv, Douglas Love, Jennifer Lew, Michael Overdorf, Muneer A Satter and Ted Yednock.
View institutional ownership trends
.

How do I buy shares of Annexon?

Shares of ANNX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ANNX) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners